Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04056910 · ClinicalTrials.gov registry record · Phase 2
Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors
A Phase 2 study of Advanced Solid Tumor and Glioma, sponsored by Jason J. Luke, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT04056910 is a Phase 2 study of Advanced Solid Tumor and Glioma that has completed, run by Jason J. Luke, MD. The registered enrollment target is 15 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04056910, a Phase 2 study of Advanced Solid Tumor and Glioma, has completed, sponsored by Jason J. Luke, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, response to treatment and (progression free and overall) survival will be described and safety events of ivosidenib in combination with nivolumab will be summarized in patients with advanced solid tumors (nonresectable or metastatic) or enhancing gliomas.
Conditions Studied
Interventions
- DRUG ivosidenib and nivolumab
Study Locations (1)
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-09-20 |
| Est. Completion | 2023-11-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04056910
The ClinicalTrials.gov registry entry for NCT04056910 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (92% lower). The listed sponsor is Jason J. Luke, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which ivosidenib and nivolumab is the first listed.
NCT04056910 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04056910 about?
NCT04056910 is a clinical study titled "Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors". In this study, response to treatment and (progression free and overall) survival will be described and safety events of ivosidenib in combination with nivolumab will be summarized in patients with advanced solid tumors (nonresectable or metastatic) or enhancing gliomas.
What is the current status of trial NCT04056910?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2021-09-20. Estimated completion is 2023-11-13.
What conditions does trial NCT04056910 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Glioma, IDH1 Mutation.
What interventions are being tested in trial NCT04056910?
The interventions under investigation include: ivosidenib and nivolumab (DRUG).
Who is sponsoring clinical trial NCT04056910?
This trial is sponsored by Jason J. Luke, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04056910 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
RECRUITING · Phase 2
-
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
RECRUITING · Phase 2
-
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 2
-
Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations
ACTIVE NOT RECRUITING · Phase 2
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.